摘要
树突状细胞（dendritic cell，DC）是体内最强大的抗原呈递细胞（antigen presenting cell，APC），可在体内外向T细胞提呈肿瘤细胞的抗原，并诱发细胞毒性T淋巴细胞（CTL）反应，发挥抗肿瘤作用。在体内外用现代分子生物学技术，将肿瘤细胞、裂解的肿瘤细胞成分或肿瘤细胞的凋亡产物、肿瘤mRNA或DNA等修饰DC制成瘤苗，或者提取肿瘤患者DC中的Dexosomes制成疫苗等基于DCs的免疫疗法，为肿瘤患者的治疗开辟了一种新的途径，具有极其广阔的前景。
Dendritic cells （DC） , the most potent antigen-presenting cells in vivo, can present tumor antigens to T cells in vivo and in vitro. DCs can also stimulate the antigen-specific cytotoxic T lymphocyte responses and further induce antitumor immunity. By modem in vivo and in vitro molecular biological technologies we can modify DCs with tumor cell,lytic tumor cells components,apoptotic products of tumor cells .mRNAs or DNAs of tumor cells ,and can extract dexosomes of DCs from tumor patients to make tumor vaccines. All these can be used for therapeutic cancer vaccines and have a promising future.
出处
《国际免疫学杂志》
CAS
2007年第3期151-154,共4页
International Journal of Immunology
基金
首都医学发展科研基金资助项目（2003-3086）
